Elsevier

Cytokine

Volume 98, October 2017, Pages 42-50
Cytokine

STAT3 in cancer: A double edged sword

https://doi.org/10.1016/j.cyto.2017.03.018Get rights and content

Highlights

  • STAT3 can behave both as an oncogene and an oncosuppressor.

  • Activation by many signals and heterogeneous target genes can explain this feature.

  • Specific post-translational modifications dictate different cellular localization.

  • These activities contribute to regulate energy metabolism and autophagy.

  • Finally, STAT3 controls the properties of both the tumor and its microenvironment.

Abstract

The transcription factor signal transducer and activator of transcription (STAT) 3 is activated downstream of cytokines, growth factors and oncogenes to mediate their functions under both physiological and pathological conditions. In particular, aberrant/unrestrained STAT3 activity is detected in a wide variety of tumors, driving multiple pro-oncogenic functions. For that, STAT3 is widely considered as an oncogene and is the object of intense translational studies. One of the distinctive features of this factor is however, its ability to elicit different and sometimes contrasting effects under different conditions. In particular, STAT3 activities have been shown to be either pro-oncogenic or tumor-suppressive according to the tumor aetiology/mutational landscape, suggesting that the molecular bases underlining its functions are still incompletely understood. Here we discuss some of the properties that may provide the bases to explain STAT3 heterogeneous functions, and in particular how post-translational modifications contribute shaping its sub-cellular localization and activities, the cross talk between these activities and cell metabolic conditions, and finally how its functions can control the behaviour of both tumor and tumor microenvironment cell populations.

Introduction

Signal Transducer and Activator of Transcription (STAT) factors become activated downstream of both extrinsic and intrinsic signals by phosphorylation on a conserved tyrosine residue mainly accomplished by receptor-associated JAK kinases [1], [2]. Tyrosine-phosphorylated (YP)-STATs form active dimers that concentrate in the nucleus to regulate the expression of target genes [3]. The family member STAT3 is canonically activated by YP downstream of numerous cytokines, growth factors and oncogenes, and is accordingly constitutively active in a high percentage of tumors and tumor-derived cell lines of both liquid and solid origin, which often become STAT3 addicted (recently reviewed by [4], [5]). Thus, STAT3 is widely considered as an oncogene and a good target for anti-cancer therapy. In keeping with the wide repertoire of distinct target genes activated in different contexts, STAT3 was reported to exert a plethora of different functions in normal as well as in transformed cells. STAT3 constitutive activity in tumours can promote cell survival and proliferation, down-modulate anti-tumour immune responses and promote tumor angiogenesis, enhance tumour invasion and metastasis by inducing epithelial to mesenchymal transition (EMT), alter the extracellular matrix through the expression of matrix metalloproteinases (MMP) and the enhancement of collagen cross-linking and tissue tension, modify cell energy metabolism and mitochondrial activity. Finally, STAT3 activity can confer tumor-initiating features to cancer cells in a number of solid tumors [4], [6], [7], [8], [9].

Not surprisingly therefore, STAT3 transcriptional functions are required for cellular transformation downstream of several oncogenes that trigger its phosphorylation on Y705 such as, for example, Src [10]. However, STAT3 is also required for Ras-mediated tumor transformation, for which YP and transcriptional activities are dispensable [11], suggesting that both transcriptional and non-transcriptional activities of STAT3 promote tumorigenesis. Despite this knowledge, and the wealth of data supporting the concept of STAT3 as an oncogene, several reports have now highlighted its ability to suppress tumor onset and/or progression.

Section snippets

STAT3 the oncogene or STAT3 the oncosuppressor?

The first indication that STAT3 tumor-promoting functions may be strongly context-dependent came from the observation that STAT3 plays a dual role in glioblastoma, and this role depends on its mutational status. While in the context of tumors driven by the type III epidermal growth factor receptor (EGFRvIII) mutation STAT3 triggered glial transformation by associating with the mutant receptor in the nucleus, in the context of PTEN loss STAT3 inhibited glial tumor transformation and growth [12].

Tyrosine phosphorylation

As mentioned in the introduction, STAT3 canonical activity as a transcription factor mainly depends on JAK kinase-mediated phosphorylation on Y705 (YP), which endows STAT3 dimers with the ability to concentrate in the nucleus, bind to DNA and activate transcription. Upstream signals that can trigger STAT3 YP range from cytokines of the IL-6 family, leptin, IL-12, IL-17, IL-10, Interferons, growth factors such as G-CSF, EGF, PDGF, and a number of oncogenes, the prototype of which are Src family

STAT3 and energy metabolism: of electron transport complexes and transcription

Energy metabolism plays a central role in tumor progression, with tumor cells often undergoing a metabolic switch known as the Warburg effect, leading to increased aerobic glycolysis and reduced mitochondrial activity [57]. STAT3 is an important player in this switch, since its constitutive transcriptional activity promotes aerobic glycolysis and down regulates mitochondrial activity by inducing HIF1α transcription while reducing the expression of electron transport complexes (ETC) [58]. In

STAT3 and redox balance: to be or not to be (oxidized)

Redox homeostasis is maintained thanks to an equilibrium between ROS production and scavenging, whose disruption may result in oxidative stress which in turn contributes to the pathogenesis of cancer, neurodegeneration and aging [77]. While controlled ROS production is involved in the signaling of growth factor and cytokine receptors, an excess of ROS can directly lead to oxidation-mediated inactivation of several protein phosphatases, indirectly activating key proliferation and survival

STAT3 as an autophagy regulator: to eat or not to eat (itself)

Autophagy, and in particular macro-autophagy, is a cellular process that delivers cytoplasmic material to lysosomes for degradation [84], and it plays ambiguous roles in tumor transformation and progression [85]. While an efficient autophagy machinery is essential to protect cells from transformation, cancer cells rely on autophagy for their survival and diffusion. Thus, fine-tuning of the autophagy process may represent an appealing strategy for both prevention and therapy of cancer. The

Both seed and soil: STAT3 and the tumor microenvironment

Tumor growth relies on the establishment of reciprocal relationships with components of the tumor microenvironment (TME), which is composed of cells of hematopoietic and mesenchymal origin. TME cell components can be either stromal resident cells or be specifically recruited to the tumor site, where they are instructed by cancer cells to acquire pro-tumorigenic features [106]. The reciprocal crosstalk among different cell types is responsible for the establishment and maintenance of the

Concluding remarks

Despite the concept of oncogenic STAT3 being widely accepted, an increasing body of data now supports the view that STAT3 functions are too variegated to be easily classified. Ultimately, the specific cellular role of STAT3 is determined by the integration of multiple signals that dictate the overall abundance of its many differentially modified forms, and consequently their sub-cellular localization and activity (see Fig. 1). Direct modulation by oxidation suggests that the effects of upstream

Acknowledgments

Work in the authors’ laboratories is supported by grants from the Italian Cancer Research Association (AIRC IG16930), the San Paolo Foundation, the Italian Ministry for the University and Research (MIUR PRIN) and the Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, to V.P. L.A. and A. Camperi were the recipients of an Italian Cancer Research Foundation (FIRC) post-doctoral fellowship. A. Camporeale was the recipient of a Fondazione Veronesi post-doctoral fellowship. The authors wish to

References (152)

  • M. Bernier et al.

    Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein

    J. Biol. Chem.

    (2011)
  • E. Kim et al.

    Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells

    Cancer Cell

    (2013)
  • C. Mantel et al.

    Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype

    Blood

    (2012)
  • P. Tammineni et al.

    The import of the transcription factor STAT3 into mitochondria depends on GRIM-19, a component of the electron transport chain

    J. Biol. Chem.

    (2013)
  • K. Szczepanek et al.

    Mitochondrial-targeted signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species

    J. Biol. Chem.

    (2011)
  • Q. Zhang et al.

    Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727

    J. Biol. Chem.

    (2013)
  • E. Macias et al.

    Stat3 binds to mtDNA and regulates mitochondrial gene expression in keratinocytes

    J. Invest. Dermatol.

    (2014)
  • D.J. Gough et al.

    STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation

    Blood

    (2014)
  • J.K. Lee et al.

    NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases

    Gastroenterology

    (2007)
  • Z. Zhong et al.

    Autophagy, inflammation, and immunity: a troika governing cancer and its treatment

    Cell

    (2016)
  • J. Guo et al.

    Downregulation of miR-17-92a cluster promotes autophagy induction in response to celastrol treatment in prostate cancer cells

    Biochem. Biophys. Res. Commun.

    (2016)
  • S. Shen et al.

    Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity

    Mol. Cell

    (2012)
  • C. Mammucari et al.

    FoxO3 controls autophagy in skeletal muscle in vivo

    Cell Metab.

    (2007)
  • H.M. Oh et al.

    STAT3 protein interacts with Class O Forkhead transcription factors in the cytoplasm and regulates nuclear/cytoplasmic localization of FoxO1 and FoxO3a proteins in CD4(+) T cells

    J. Biol. Chem.

    (2012)
  • J. Turkson et al.

    STAT proteins: novel molecular targets for cancer drug discovery

    Oncogene

    (2000)
  • K. Siddiquee et al.

    Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

    Proc. Natl. Acad. Sci. U.S.A

    (2007)
  • H. Yu et al.

    Revisiting STAT3 signalling in cancer: new and unexpected biological functions

    Nat. Rev. Cancer

    (2014)
  • J. Yuan et al.

    Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

    Sci. Rep.

    (2015)
  • H. Yu et al.

    STATs in cancer inflammation and immunity: a leading role for STAT3

    Nat. Rev. Cancer

    (2009)
  • L. Avalle et al.

    Universal and specific functions of Stat3 in solid tumors

  • M. Demaria et al.

    STAT3 and metabolism: how many ways to use a single molecule?

    Int. J. Cancer

    (2014)
  • H. Laklai et al.

    Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression

    Nat. Med.

    (2016)
  • J.F. Bromberg et al.

    Stat3 activation is required for cellular transformation by v-src

    Mol. Cell. Biol.

    (1998)
  • D.J. Gough et al.

    Mitochondrial STAT3 supports Ras-dependent oncogenic transformation

    Science

    (2009)
  • N. de la Iglesia et al.

    Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway

    Genes Dev.

    (2008)
  • J. Pencik et al.

    STAT3 regulated ARF expression suppresses prostate cancer metastasis

    Nat. Commun.

    (2015)
  • B. Grabner et al.

    Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis

    Nat. Commun.

    (2015)
  • M. Musteanu et al.

    Stat3 is a negative regulator of intestinal tumor progression in ApcMin mice

    YGAST

    (2010)
  • J.P. Couto et al.

    STAT3 negatively regulates thyroid tumorigenesis

    Proc. Natl. Acad. Sci. U.S.A

    (2012)
  • J.E. Yeh et al.

    STAT3-interacting proteins as modulators of transcription factor function: implications to targeted cancer therapy

    ChemMedChem

    (2016)
  • V. Poli et al.

    STAT3-mediated metabolic reprograming in cellular transformation and implications for drug resistance

    Front. Oncol.

    (2015)
  • T. Bowman et al.

    STATs in oncogenesis

    Oncogene

    (2000)
  • R. Catlett-Falcone et al.

    STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription

    Curr. Opin. Oncol.

    (1999)
  • H. Lee et al.

    STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

    Nat. Med.

    (2010)
  • D. Xu et al.

    Protein tyrosine phosphatases in the JAK/STAT pathway

    Front. Biosci.

    (2008)
  • M.M. Rytinki et al.

    PIAS proteins: pleiotropic interactors associated with SUMO

    Cell. Mol. Life Sci.: CMLS

    (2009)
  • E.M. Linossi et al.

    Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins

    Immunol. Rev.

    (2015)
  • D.L. Krebs et al.

    SOCS proteins: negative regulators of cytokine signaling

    Stem Cells

    (2001)
  • C.D. Chung et al.

    Specific inhibition of Stat3 signal transduction by PIAS3

    Science

    (1997)
  • C.M. Silva

    Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis

    Oncogene

    (2004)
  • Cited by (0)

    View full text